Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair
Open Access
- 26 June 2018
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy Nucleic Acids
- Vol. 12, 554-567
- https://doi.org/10.1016/j.omtn.2018.06.008
Abstract
No abstract availableFunding Information
- Institut National de la Santé et de la Recherche Médicale
- Dystrophic Epidermolysis Bullosa Association (DEBRA) France
- Association Française contre les Myopathies
- European Research Council (ERC-2010-AdG, GT-SKIN)
- AFM (DEBTALENS-AFM)
This publication has 66 references indexed in Scilit:
- A Survey of Validation Strategies for CRISPR-Cas9 EditingScientific Reports, 2018
- In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophyScience, 2016
- Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosaEuropean Journal of Dermatology, 2015
- GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleasesNature Biotechnology, 2014
- Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effectsNature Methods, 2014
- Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrixThe Lancet, 2013
- Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing SpecificityCell, 2013
- TALEN-based Gene Correction for Epidermolysis BullosaMolecular Therapy, 2013
- Integration-deficient Lentiviral Vectors: A Slow Coming of AgeMolecular Therapy, 2009
- Highly efficient endogenous human gene correction using designed zinc-finger nucleasesNature, 2005